Table 2 Efficacy outcomes
Fotemustine efficacy | Interferon-α2b efficacy | |||||
|---|---|---|---|---|---|---|
FM/DTIC/IFN + FM/DTIC | DTIC/IFN + DTIC | HR* (95% CI) | FM/DTIC/IFN + DTIC/IFN | FM/DTIC + DTIC | HR* (95% CI) | |
Overall survival: | ||||||
Events, n (%) | 125 (95%) | 125 (98%) | 122 (97%) | 128 (96%) | ||
Median, months (95% CI) | 7.9 (6.6−10.2) | 8.6 (6.3−10.4) | 0.93 (0.71−1.21) | 9.1 (6.3−11.1) | 7.7 (6.3−9.7) | 0.92 (0.70−1.20) |
Progression-free survival: | ||||||
Events, n (%) | 128 (97%) | 125 (98%) | 123 (98%) | 130 (97%) | ||
Median, months (95% CI) | 2.7 (2.4−3.8) | 2.5 (2.3−3.7) | 0.93 (0.72−1.21) | 2.8 (2.4−3.9) | 2.5 (2.3−2.9) | 0.96 (0.73−1.25) |
Overall response, n (%) | 32 (34%) | 33 (26%) | 34 (27%) | 31 (23%) | ||
(95% CI) | (17−32%) | (18−33%) | (19−35%) | (16−30%) | ||